Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Pulmonary arterial hypertension (PAH) occurs as an idiopathic process or as a component of a variety of disease processes, including chronic thromboembolic disease, connective tissue diseases, congenital heart disease, and exposure to exogenous factors including appetite suppressants or infectious agents such as HIV. This article reviews evidence for screening in susceptible patient groups and the approach to diagnosing PAH when it is suspected, and provides specific recommendations for applying this evidence to clinical practice.
McGoon
Michael
M
Mayo Clinic, Rochester, USA.
Gutterman
David
D
Steen
Virginia
V
Barst
Robin
R
McCrory
Douglas C
DC
Fortin
Terry A
TA
Loyd
James E
JE
D004452:Echocardiography; D004562:Electrocardiography; D020022:Genetic Predisposition to Disease; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000235:genetics; D008403:Mass Screening / Q000379:methods / Q000592:standards*; D010808:Physical Examination; D011651:Pulmonary Artery; D013902:Radiography, Thoracic; D012307:Risk Factors